Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva And Kowa Partner For 50-50 Stake In Japanese Generic Firm

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japanese drug maker Kowa said Sept. 24 that it had signed a definitive agreement with Israel generic manufacturer Teva Pharmaceutical to share a 50-50 stake in a generic manufacturer in Japan to take advantage of a growing Japanese generics market

You may also be interested in...



Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers

Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market

Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers

Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market

Battling Negative Image Of Generics In Japan (Part 2 of 2)

[Editor's note: This is part two of a two-part feature on obstacles in promoting generics in Japan. Part one, which explored negative connotations associated with with the term "generic," appeared in PharmAsia News, March 19, 2009.]

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel